MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
MS Therapy Laquinimod Fails to Meet Key Trial Goal of Slowing the Disease
Laquinimod (Nerventra, ABR-215062) - Multiple Sclerosis News Today
425
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis | Neurology
PDF) Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis for the ALLEGRO Study Group
Teva Pharmaceuticals - Wikiwand
![Multiple Sclerosis: KOL Insight [2017]](https://cdn11.bigcommerce.com/s-wwae5/images/stencil/1280x1280/products/890/2562/596200878-TT-MS__36264.1511454609.png?c=2 "Multiple Sclerosis: KOL Insight [2017]")
Multiple Sclerosis: KOL Insight [2017]
Potential Huntington's Therapy Laquinimod Fails Primary Objective in Phase 2 Trial
Teva Pharmaceuticals - Wikipedia
Earnings Preview: What To Expect From Teva Pharmaceutical On Monday
Teva returns laquinimod global rights to Active Biotech
Teva Showcases CNS Portfolio at 69th Annual Meeting of the American Academy of Neurology - Global Genes
Meet the Compound: Laquinimod – HD Insights
Teva May Have to Make Difficult Capital Allocation Decisions Under Pressure From Potential Generic Competition, Deleveraging Goals - Reorg
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women | Request PDF
Teva's MS pill misses the mark in PhIII trial - PharmaTimes
Teva drops laquinimod for most common form of MS after failed trial - PMLiVE
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS | Journal of Neuroinflammation | Full Text
Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint - Chemdiv
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
